|
|
|
|
 |
Nanogen Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu |
| Companies mentioned in this article: |
|
Nanogen |
|
| 6/5/2008 @ 1:52 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced today it has been awarded a new $10.4 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a multi-analyte molecular diagnostic assay for Influenza. This new contract will have Nanogen develop a fast molecular test that simultaneously detects and differentiates Influenza Type A, Influenza Type B, seasonal flu (H1N1 and H3N2) strains, and Respiratory Syncytial Virus (RSV). The contract provides for a secondary, “reflex”, test for avian flu strains (H5N1, H7N1, and H9N1) to be available for samples that are determined to be positive for Flu A but negative for seasonal flu. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age.
The molecular diagnostic test will be developed in partnership with the Medical College of Wisconsin (MCW) and HandyLab Inc. It will be significantly more sensitive than current rapid flu tests and is expected to be conducted in less than half the time it takes to run current molecular tests. These tests are intended as a key component of the CDC's two-pronged approach to quickly identify and respond to a potential flu pandemic.
This is the second contract the Company has been awarded by the CDC related to the development of diagnostic tests for influenza and complements the rapid test currently being developed by the Company in collaboration with HX Diagnostics (see Company press release from December 2006 for information on the rapid point-of-care diagnostic test project).
"Receiving a second significant contract from the CDC is a strong endorsement of our capabilities as a diagnostic company and clearly shows recognition for our expertise in molecular biology and infectious disease. Additionally, this contract will increase funds for ongoing development of our market-leading, real-time PCR technology and an integrated system to improve ease of use in clinical laboratories," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. “Recently there have been a number of multiplexed molecular products for respiratory targets to hit the market. These products, however, are expensive and test for more pathogens than are useful in clinical diagnosis. Having a fast molecular assay that can be used as a confirmatory test for influenza will improve the tools available to clinicians for better patient health management. We are excited and pleased to partner with MCW and HandyLab on this project.”
This molecular diagnostics development program will incorporate assay development that Nanogen has been working on in cooperation with MCW as part of an NIH grant for multiplexed infectious disease diagnostics. The proposal to the CDC included the use of Nanogen’s proprietary MGB probe technology for real-time PCR and anticipates the use of off-the-shelf instrumentation for sample handling and detection, including the HandyLab, Inc., Raider instrument, a microfluidic real-time PCR technology, which will significantly shorten time to result.
This contract further extends a longstanding partnership between Nanogen and Dr. Kelly Henrickson by utilizing MCW’s new Midwest Respiratory Virus Program. Dr. Henrickson said, “Success in this project will significantly advance multiplex PCR use in the clinical laboratory and provide a unique hands off solution for rapid, sensitive and specific detection of seasonal respiratory viruses and pandemic influenza.”
“Our collaboration with Nanogen on this project validates Raider’s performance for microfluidic real-time PCR technology,” said Mark Powelson, HandyLab’s Vice President of Sales and Marketing, “Our technology contribution to this project is anticipated to redefine the way respiratory testing is done.”
Each year, 5 percent to 20 percent of the U.S. population is affected by the influenza virus with approximately 36,000 deaths caused by the infection. Healthcare agencies, like the CDC, are concerned about the possibility of a deadly subtype, like avian flu, rapidly emerging and causing a pandemic. By 2010, the worldwide influenza diagnostics market is likely to reach $200 million.
About Nanogen, Inc.
Nanogen, Inc., develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen's website at www.nanogen.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, October 3, 2008 |
 |
|
Essentialis Announces Two Presentations at Upcoming Conferences Posted 6:19 AM PST
|
| |
| Thursday, October 2, 2008 |
|
|
SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis Posted 1:08 PM PST
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain Posted 10:41 AM PST
|
| |
| Wednesday, October 1, 2008 |
|
|
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel Posted 6:07 PM PST
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society Posted 6:04 PM PST
University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia Posted 3:52 PM PST
BioMed Realty Trust Announces Public Offering of 7,500,000 Shares of Common Stock Posted 3:51 PM PST
SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. Posted 3:48 PM PST
Halozyme Therapeutics to Host Research Day for Investors and Analysts Posted 3:46 PM PST
Bio-Matrix Scientific Group, Inc. Receives and Processes First Cord Blood Specimens as Part of the Company’s Quality Assurance Program Posted 7:15 AM PST
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference Posted 4:33 AM PST
|
| |
| Tuesday, September 30, 2008 |
|
|
Genoptix Announces Participation at the Second Annual William Blair Small Cap Growth Conference Posted 10:15 AM PST
Cytori Receives Key Patent for its Cosmetic & Reconstructive Surgery Product Posted 7:54 AM PST
|
| |
| Monday, September 29, 2008 |
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference Posted 4:46 PM PST
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting Posted 8:43 AM PST
Bio-Quant Announces the Expansion of Its Research Animal Diagnostic Services to Cover All Nine Species Posted 8:27 AM PST
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Posted 8:09 AM PST
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008 Posted 7:44 AM PST
|
| |
| Thursday, September 25, 2008 |
|
|
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds Posted 9:18 AM PST
CytRx Corporation to Present New Data from Its Proprietary Molecular Chaperone Drug Discovery Technology at the San Diego LEADS Meeting Posted 8:55 AM PST
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 7:53 AM PST
|
| |
| Wednesday, September 24, 2008 |
|
|
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients Posted 3:09 PM PST
ChemBridge Corporation Enters Into New Discovery Chemistry Strategic Alliance With AstraZeneca Posted 6:40 AM PST
|
| |
| Tuesday, September 23, 2008 |
|
|
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes Posted 4:37 PM PST
Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing Posted 2:54 PM PST
Ebioscience Expands Multicolor Cellular Analysis Portfolio With Introduction of eFluor Brand and Commercial Launch of eFluor Nanocrystal Product Line Posted 8:52 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
